Morning vs. afternoon immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these advanced or metastatic cancers: non-small cell lung cancer, head and neck cancer, kidney cancer, bile duct cancer, liver cancer, or melanoma.
- You must be scheduled to start a new immunotherapy (like a PD-1 or PD-L1 inhibitor) that the FDA has approved.
- You must not have received immunotherapy for your cancer before.
- You must not be taking strong immune-suppressing drugs (like high-dose steroids) within the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving immunotherapy (medicines that help your immune system fight cancer) at specific times of day—aligned with your body's natural rhythms—works better for advanced melanoma. Researchers will randomly assign you to receive treatment either on a timed schedule or a standard schedule.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
This trial tests whether giving immunotherapy (nivolumab and ipilimumab) at a specific time of day can improve survival in people with advanced kidney cancer. It compares infusions before 11:30 a.m. versus after 1:30 p.m.
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
Hear when a new Advanced Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.